Condition: HIV-1-infection · Sponsor: Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
The main objective of the MODULO trial is to compare (non-inferiority) the capacity of DOR/3TC and DTG/3TC two-drug regimens of maintain virological success at W48 in people living with HIV virus ( PLWH) with suppressed HIV plasma viral load (pVL) under three-drug regimen at inclusion. The virological success is defined as no virological failure (2 consecutive pVL ≥50 copies/mL or one pVL ≥50 copies/mL followed with discontinuation of treatment or follow-up).
This description comes directly from the study's public registry record.
Yasmine DUDOIT · +33 (0)142164181 · yasmine.dudoit@aphp.fr
Romain PALICH, MD · +33 (0)142160171 · romain.palich@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Pitié-Salpêtrière | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06774872